The Diabetes Australia 2016–2018 guidelines favor adding an SU, a DPP-4 inhibitor, or an SGLT2 inhibitor and if necessary, the addition of any of the above with GLP-1 agonists or insulin. This evidence concerns the gene GLP1R and diabetes mellitus.